ADSC Therapy for Autoimmune Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Pre-clinicalInferred R&D
Key Facts
Indication
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Phase
Pre-clinical
Status
Inferred R&D
Company
About A4Cell
A4Cell is a pioneering regenerative medicine company leveraging adipose-derived stem cells (ADSCs) to develop novel therapies for unmet medical needs. Its core technology platform isolates and expands potent stem cells from fat tissue, offering a minimally invasive and abundant cell source. The company is advancing a pipeline of cell therapy candidates targeting conditions like osteoarthritis, Crohn's disease, and other inflammatory disorders. As a private, research-stage biotech, A4Cell is positioned to capitalize on the growing cell therapy market through strategic development and potential partnerships.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis, Systemic Lupus Erythematosus Drugs
| Drug | Company | Phase |
|---|---|---|
| ARD-885 | Artivila Therapeutics | Phase 2 |